# OMO-1 in Solid Malignancies

> **NCT03138083** · PHASE1,PHASE2 · TERMINATED · sponsor: **Octimet Oncology N.V.** · enrollment: 40 (actual)

## Conditions studied

- Neoplasms

## Interventions

- **DRUG:** OMO-1

## Key facts

- **NCT ID:** NCT03138083
- **Lead sponsor:** Octimet Oncology N.V.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2017-08-08
- **Primary completion:** 2020-05-25
- **Final completion:** 2020-05-25
- **Target enrollment:** 40 (ACTUAL)
- **Why stopped:** strategic reasons (not due to lack of efficacy or safety issues)
- **Last updated:** 2020-06-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03138083

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03138083, "OMO-1 in Solid Malignancies". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT03138083. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*